Patents Represented by Attorney Tonya L. Combs

Find this attorney in the Justia Lawyer Directory

  • AMPA receptor potentiators
    Patent number: 8097652
    Abstract: The present invention relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof which is useful for the treatment of conditions associated with glutamate hypofunction, such as psychiatric and neurological disorders.
    Type: Grant
    Filed: December 6, 2007
    Date of Patent: January 17, 2012
    Assignee: Eli Lilly and Company
    Inventor: Esteban Dominguez-Manzanares
  • AMPA receptor potentiators
    Patent number: 7652064
    Abstract: The present invention relates to AMPA receptor potentiators of Formula I: formulations comprising them, methods for their use, and intermediates useful for their preparation.
    Type: Grant
    Filed: June 6, 2006
    Date of Patent: January 26, 2010
    Assignee: Eli Lilly and Company
    Inventor: Esteban Dominguez-Manzanares
  • Thiophene and furan compounds
    Patent number: 7642361
    Abstract: The present invention relates to thiophene and furan compounds and their pharmaceutically acceptable salts, and further relates to their use in treating schizophrenia, cognitive deficits associated with schizophrenia, Alzheimer's disease, dementia of the Alzheimer's type, mild cognitive impairment, or depression.
    Type: Grant
    Filed: January 5, 2005
    Date of Patent: January 5, 2010
    Assignee: Eli Lilly and Company
    Inventors: Ana Maria Castano Mansanet, Esteban Dominguez-Manzanares, Ana Maria Escribano, Maria Carmen Fernandez, William Joseph Hornback, Alma Maria Jimenez-Aguado, Eric George Tromiczak, Zhipei Wu, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
  • Pyrrole and pyrazole derivatives as potentiators of glutamate receptors
    Patent number: 7625932
    Abstract: The present invention relates to pyrrole and pyrazole compounds of formula (I) and their pharmaceutically acceptable salts, and further relates to their use in treating schizophrenia, cognitive deficits associated with schizophrenia, Alzheimer's disease, dementia of the Alzheimer's type, mild cognitive impairment, or depression. The compounds act as potentiators on glutamate receptors, in particular AMPA and the GluR family.
    Type: Grant
    Filed: August 27, 2004
    Date of Patent: December 1, 2009
    Assignee: Eli Lilly and Company
    Inventors: Pamela Ann Albaugh, Esteban Dominguez-Manzanares, Jian Eric Hong, William Joseph Hornback, Delu Jiang, Paul Leslie Ornstein, Michelle Lee Thompson, Eric George Tromiczak, Zhipei Wu, Hamideh Zarrinmayeh, Dennis Michael Zimmerman, Ana Maria Castano Mansanet, Larry Gene Huffman, William David Miller
  • 3-Aminopyrrolidines as inhibitors of monoamine uptake
    Patent number: 7619096
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, which are useful for the inhibition of the uptake of one or more physiologically active monoamines (serotonin, norepinephrine, and dopamine).
    Type: Grant
    Filed: May 11, 2004
    Date of Patent: November 17, 2009
    Assignee: Eli Lilly and Company
    Inventors: Christopher David Beadle, Manuel Javier Cases-Thomas, Barry Peter Clark, Peter Thaddeus Gallagher, John Joseph Masters, Graham Henry Timms, Magnus Wilhelm Walter, Maria Ann Whatton, Virginia Ann Wood, Jeremy Gilmore
  • Morpholine derivatives as norepinephrine reuptake inhibitors
    Patent number: 7595315
    Abstract: Compounds of the general formula (I) are inhibitors of the reuptake of norepinephrine. As such, they may be useful for the treatment of disorders of the central and/or peripheral nervous system.
    Type: Grant
    Filed: December 10, 2004
    Date of Patent: September 29, 2009
    Assignee: Eli Lilly and Company
    Inventors: Peter Thaddeus Gallagher, Carlos Lamas-Peteira, Francisco Javier Agejas-Chicharro
  • Process for the asymmetric synthesis of duloxetine
    Patent number: 7538232
    Abstract: This invention provides an improved asymmetric process for the synthesis of duloxetine involving arylation of Compounds of Formula I.
    Type: Grant
    Filed: January 19, 2006
    Date of Patent: May 26, 2009
    Assignee: Eli Lilly and Company
    Inventors: Mark Anthony Butchko, Alain Merschaert, Kenneth Philip Moder
  • 3-aminopiperidines and 3-aminoquinuclidines as inhibitors of monoamine uptake
    Patent number: 7432280
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, which are useful for the inhibition of the uptake of one or more physiologically active monoamines (serotonin, norepinephrine, and dopamine).
    Type: Grant
    Filed: May 25, 2004
    Date of Patent: October 7, 2008
    Assignee: Eli Lilly and Company
    Inventors: Christopher David Beadle, Manuel Javier Cases-Thomas, Barry Peter Clark, Peter Thaddeus Gallagher, John Joseph Masters, Graham Henry Timms, Magnus Wilhelm Walter, Maria Ann Whatton, Virginia Ann Wood, Jeremy Gilmore
  • AMPA receptor potentiators
    Patent number: 7393868
    Abstract: The present invention relates to AMPA receptor potentiators of Formula I: formulations comprising them, methods for their use, and intermediates useful for their preparation.
    Type: Grant
    Filed: June 5, 2006
    Date of Patent: July 1, 2008
    Assignee: Eli Lilly and Company
    Inventors: Ana Maria Castano Mansanet, Frederic Laurent Cordier, Esteban Dominguez-Manzanares, Jian Eric Hong, William Joseph Hornback, Delu Jiang
  • Benzenesulfonic acid indol-5-yl esters as antagonists of the 5ht receptor
    Patent number: 7230011
    Abstract: The present invention relates to compounds of formula I: which are antagonists of 5-HT6 receptor.
    Type: Grant
    Filed: January 17, 2002
    Date of Patent: June 12, 2007
    Assignee: Eli Lilly and Company
    Inventors: Sandra Ann Filla, Michael Edward Flaugh, James Ronald Gillig, Lawrence Joseph Heinz, Joseph Herman Krushinski, Jr., Bin Liu, Marta Maria Pineiro-Nunez, John Mehnert Schaus, John Stanley Ward
  • N-(2-Arylethyl) benzylamines as antagonists of the 5-HTreceptor
    Patent number: 7157488
    Abstract: The present invention provides compounds of formula I pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are antagonists of the 5-HT6 receptor. The present invention further provides a method of treating disorders associated with 5-HT6 receptors, including schizophrenia, anxiety, Alzheimer's disease, and cognitive disorders selected from the group consisting of age-related cognitive decline, mild cognitive impairment, and dementia, comprising: administering to a patient in need thereof an effective amount of a compound of formula I.
    Type: Grant
    Filed: March 15, 2002
    Date of Patent: January 2, 2007
    Assignee: Eli Lilly and Company
    Inventors: Zhaogen Chen, Michael Philip Cohen, Matthew Joseph Fisher, Bruno Giethlen, James Ronald Gillig, Jefferson Ray McCowan, Shawn Christopher Miller, John Mehnert Schaus